{ "ok": true, "cik": "721371", "ticker": "CAH", "name": "Cardinal Health, Inc.", "filings": [ { "form": "DEF 14A", "filed": "2026-09-21", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/721371/000130817926000402/0001308179-26-000402-index.htm" }, { "form": "10-K", "filed": "2026-08-11", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/721371/000072137126000038/0000721371-26-000038-index.htm" }, { "form": "8-K", "filed": "2026-08-11", "items": [ "2.02 Results of Operations and Financial Condition", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/721371/000072137126000037/0000721371-26-000037-index.htm" }, { "form": "8-K", "filed": "2026-08-11", "items": [ "1.01 Entry into a Material Definitive Agreement", "1.02 Termination of a Material Definitive Agreement", "2.03 Creation of a Direct Financial Obligation", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/721371/000072137126000036/0000721371-26-000036-index.htm" }, { "form": "8-K", "filed": "2026-08-05", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers" ], "url": "https://www.sec.gov/Archives/edgar/data/721371/000072137126000026/0000721371-26-000026-index.htm" }, { "form": "10-Q", "filed": "2026-04-30", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/721371/000072137126000018/0000721371-26-000018-index.htm" } ], "events12m": 12, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000721371.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=721371" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up Cardinal Health, Inc. ($CAH). Last filing: DEF 14A, 2026-09-21. 12 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2026-06-30", "revenue": 254248000000, "revenueGrowth1y": 0.1422871981956888, "revenueGrowthPerYear": 0.0881765582894507, "yearsOfData": 5, "operatingMargin": 0.010277366980271232, "operatingMarginPrior": 0.010221135961325917, "netMargin": 0.006741449293603096, "operatingCashFlow": 5174000000, "capitalSpending": 649000000, "freeCashFlow": 4525000000, "researchAndDevelopment": null, "researchShareOfRevenue": null, "cash": 4856000000, "longTermDebt": 8886000000, "longTermDebtChange": 0.04210155975137808, "revenueHistory": [ { "fiscalYearEnd": "2022-06-30", "revenue": 181326000000 }, { "fiscalYearEnd": "2023-06-30", "revenue": 204979000000 }, { "fiscalYearEnd": "2024-06-30", "revenue": 226827000000 }, { "fiscalYearEnd": "2025-06-30", "revenue": 222578000000 }, { "fiscalYearEnd": "2026-06-30", "revenue": 254248000000 } ], "totalEquity": -2883000000, "totalAssets": 57299000000, "equityRatio": -0.05031501422363392, "returnOnEquity": null, "dividendsPaid": 491000000, "payoutRatio": 0.2864644107351225, "dividendPerShare": 2.04, "dividendYearsRising": 18, "dividendCut": false, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "earningsPerShare": 7.27, "sharesOutstanding": 237000000, "bookValuePerShare": -12.164556962025317, "revenuePerShare": 1072.776371308017, "range80": { "low": 222734248518.22766, "high": 319616883437.97296, "baseline": 281799403489.6605, "n": 1471, "band": "b10" }, "ifPaceHeld": { "low": 222734248518.22766, "high": 319616883437.97296 } }, "edgarette": "🔖 Exposure: revenue $254.2B (FY2026), total debt $8.9B. Experience: revenue up 14.2% on the year, up 8.8% a year over 4 years; operating margin 1.0%, up from 1.0%. Soundness: equity -5.0% of assets (liabilities exceed assets), payout 28.6% of profit, dividend per share up 18 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $222.7B and $319.6B next year (method v3, set from 1,471 SEC company-years; on a year the method never saw, 83% landed inside). A range, not a forecast. Against peers (30 filers, $50M+ revenue, its industry group): operating margin 1.0% against a 1.4% median; growth 14.2% against 0.9%.", "peers": { "sic": 5122, "sicDescription": "Wholesale-Drugs, Proprietaries & Druggists' Sundries", "calendarYear": 2025, "minRevenue": 50000000, "depth": 2, "group": "51", "growth": [ 0.0089, 31 ], "opMargin": [ 0.014, 30 ], "equityRatio": [ 0.2989, 28 ], "returnOnEquity": [ -0.0465, 21 ], "payoutRatio": [ 0.2988, 10 ] }, "summary": "Cardinal Health (CAH) grew revenue 14.2% in FY2026 to $254.2 billion, operating margin 1.0%, in line with the 1.4% median for wholesale-drugs, proprietaries & druggists' sundries, equity -5.0% of assets, and dividend per share up 18 years running. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
Cardinal Health, Inc. against its own record and its peers
Operating marginPeer median 1.4%1.0%Revenue, on the yearPeer median 0.9%14.2%Equity of assetsPeer median 29.9%-5.0%Payout of profitPeer median 29.9%28.6%Gold tick: the median of 10–28 peers with $50M+ revenue in wholesale-drugs, proprietaries & druggists' sundries
", "chartHorizon": "
Handed back now, or kept to compound
Of each dollar of profit28.6% paid out71.4% keptHanded back per share$2.04up 18 years runningRevenue growth it managed14.2%last year, for comparison

Gold is paid out to shareholders; navy is kept in the business. Retained profit times return on equity is the pace a company can fund from itself. Facts from the filings, not a recommendation.

", "backtest": { "tests": 15, "hits": 14, "rate": 0.9333333333333333, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-22T14:25:08.311Z", "hash": "f3288c4f4fcb0200", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Cardinal Health (CAH) grew revenue 14.2% in FY2026 to $254.2 billion, operating margin 1.0%, in line with the 1.4% median for wholesale-drugs, proprietaries & druggists' sundries, equity -5.0% of assets, and dividend per share up 18 years running. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2026-06-30", "revenue": 254248000000, "totalDebt": 8886000000, "cash": 4856000000 }, "experience": { "revenueGrowth1y": 0.1422871981956888, "revenueGrowthPerYear": 0.0881765582894507, "operatingMargin": 0.010277366980271232, "operatingMarginPrior": 0.010221135961325917, "netMargin": 0.006741449293603096, "freeCashFlow": 4525000000 }, "soundness": { "equityRatio": -0.05031501422363392, "returnOnEquity": null, "payoutRatio": 0.2864644107351225, "dividendPerShare": 2.04, "dividendYearsRising": 18, "dividendCut": false, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 5122, "sicDescription": "Wholesale-Drugs, Proprietaries & Druggists' Sundries", "calendarYear": 2025, "minRevenue": 50000000, "depth": 2, "group": "51", "growth": [ 0.0089, 31 ], "opMargin": [ 0.014, 30 ], "equityRatio": [ 0.2989, 28 ], "returnOnEquity": [ -0.0465, 21 ], "payoutRatio": [ 0.2988, 10 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": { "low": 222734248518.22766, "high": 319616883437.97296, "baseline": 281799403489.6605, "coverage": 0.8, "method": "v3", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); range = 10th to 90th percentile of how SEC company-years of the same size band actually turned out", "calibratedOn": { "companyYears": 1471, "sizeBand": "b10" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 15, "hits": 14, "rate": 0.9333333333333333, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-22T14:25:08.311Z", "hash": "f3288c4f4fcb0200", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000721371.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=721371" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }